The currently available data does not support a deleterious impact of these agents in patients with cancer, but most of the studies examined tumor necrosis factor inhibitors (TNFi), most commonly in patients with breast cancer, and most of the studies included long-term survivors rather than patients with recently diagnosed cancer [6, 7]. The gene discussed is TNF; the disease is cancer.